With market exclusivity for regular Eylea ending, the company has positioned its high-dose version, marketed with Bayer ...
Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...
(Reuters) - U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher ...
Hosted on MSN18d
Regeneron to Report Q3 Earnings: What's in the Offing?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
https://www.tipranks.com/news/company-announcements/ceribell-inc-reports-strong-q3-2024-growth Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg ...
Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
Eylea (aflibercept) is a brand-name eye injection that’s prescribed for certain eye conditions including macular degeneration. The cost of the drug with and without insurance can depend on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback